An open-label cohort study of the improvement of quality of life and pain in de novo cervical dystonia patients after injections with 500 U botulinum toxin A (Dysport)

BMJ Open

Volumn 3, Issue 4, 2013, Pages

  Hefter, H ^a   Benecke, R ^b   Erbguth, F ^c   Jost, W ^d   Reichel, G ^e   Wissel, J ^f  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b UNIVERSITY OF ROSTOCK   (Germany)

^c KLINIKUM NÜRNBERG   (Germany)

^d DEUTSCHE KLINIK FÜR DIAGNOSTIK   (Germany)

^e Paracelsus Klinik   (Germany)

^f Kliniken Beelitz GmbH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN A;

ADULT; ANALGESIA; ARTICLE; CERVICAL DYSTONIA; DAILY LIFE ACTIVITY; DEPRESSION; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PAIN ASSESSMENT; PROSPECTIVE STUDY; QUALITY OF LIFE; SINGLE DRUG DOSE; UNSPECIFIED SIDE EFFECT;

EID: 84877703847     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2012-001853     Document Type: Article

References (17)

1. Crowner BE. Cervical dystonia: disease profile and clinical management. Phys Ther 2007;87:1511-26. (Pubitemid 350074386)
2. Van Zandijcke M. Cervical dystonia (spasmodic torticollis). Some aspects of the natural history. Acta Neurol Belg 1995; 95:210-15.
3. Velickovic M, Benabou R, Brin MF. Cervical dystonia pathophysiology and treatment options. Drugs 2001; 61:1921-43. (Pubitemid 33702490)
4. Simpson DM, Blitzer A, Brashear A, et al. Assessment: botulinum neurotoxin for the treatment of movement disorders (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2008;70:1699-706. (Pubitemid 351644138)
5. Poewe W, Deuschl G, Nebe A, et al. What is the optimal dose of botulinum toxin A in the treatment of cervical dystonia? Results of a double blind, placebo controlled, dose ranging study using Dysport. German Dystonia Study Group. J Neurol Neurosurg Psychiatry 1998;64:13-17. (Pubitemid 28156531)
6. Wissel J, Kanovsky P, Ruzicka E, et al. Efficacy and safety of a standardised 500 unit dose of Dysport (clostridium botulinum toxin type A haemaglutinin complex) in a heterogeneous cervical dystonia population: results of a prospective, multicentre, randomised, double-blind, placebo-controlled, parallel group study. J Neurol 2001;248:1073-8. (Pubitemid 34134544)
7. Truong D, Duane DD, Jankovic J, et al. Efficacy and safety of botulinum type A toxin (Dysport) in cervical dystonia: results of the first US randomized, double-blind, placebo-controlled study. Mov Disord 2005;20:783-91. (Pubitemid 41227144)
8. Truong D, Brodsky M, Lew M, et al. Long-term efficacy and safety of botulinum toxin type A (Dysport) in cervical dystonia. Parkinsonism Relat Disord 2010;16:316-23.
9. Molho ES, Agarwal N, Regan K, et al. Effect of cervical dystonia on employment: a retrospective analysis of the ability of treatment to restore premorbid employment status. Mov Disord 2009;24:1384-7.
10. Camfield L, Ben-Shlomo Y, Warner TT. Epidemiological study of Dystonia in Europe Collaborative Group impact of cervical dystonia on quality of life. Mov Disord 2002;17:838-41.
11. Ben-Shlomo Y, Camfield L, Warner T. What are the determinants of quality of life in people with cervical dystonia? J Neurol Neurosurg Psychiatry 2002;72:608-14. (Pubitemid 34462815)
12. Muller J, Kemmler G, Wissel J, et al. The impact of blepharospasm and cervical dystonia on health-related quality of life and depression. J Neurol 2002;249:842-6. (Pubitemid 34754220)
13. Hefter H, Kupsch A, Müngersdorf M, et al. A botulinum toxin A treatment algorithm for de novo management of torticollis and laterocollis. BMJ Open 2011;1:e000196.
14. Tsui JK, Eisen A, Stoessl AJ, et al. Double-blind study of botulinum toxin in spasmodic torticollis. Lancet 1986;2:245-7.
15. Muller J, Wissel J, Kemmler G, et al. Craniocervical dystonia questionnaire (CDQ-24): development and validation of a disease-specific quality of life instrument. J Neurol Neurosurg Psychiatry 2004;75:749-53. (Pubitemid 38526688)
16. Rinnerthaler M, Mueller J, Weichbold V, et al. Social stigmatization in patients with cranial and cervical dystonia. Mov Disord 2006;21:1636-40. (Pubitemid 44742191)
17. Tassorelli C, Mancini F, Balloni L, et al. Botulinum toxin and neuromotor rehabilitation: an integrated approach to idiopathic cervical dystonia. Mov Disord 2006;21:2240-3. (Pubitemid 46140449)